

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Hermann P.T. AMMON et al.) Group Art Unit: 1623
Application No.: 09/011,977) Examiner: Howard V. Owens, Jr.
Filed: June 15, 1998) Confirmation No.: 1580
For: USE OF BOSWELLIC ACID AND ITS DERIVATIVES FOR INHIBITING NORMAL AND INCREASED LEUCOCYTIC ELASTASE OR PLASMIN ACTIVITY)))))

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

A fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is enclosed.

03/11/2004 JBALINAN 00000069 09011977

02 FC:1806

180.00 OP

SECOND Information Disclosure Statement Application No. <u>09/011,977</u> Attorney's Docket No. <u>015200-054</u> Page 2

To assist the Examiner, the document is / documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date March 9, 2004

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620 3v:

Jernifer A. Topmiller, Pr Registration No. 50,435

Substitute for form 1449A/PTO & 1449B/PTO	Com	plete if Known
SECOND	Application Number	09/011,977
INFORMATION DISCLOSURE	Filing Date	June 15, 1998
STATEMENT BY APPLICANT	First Named Inventor	Hermann P.T. AMMON et al.
P C (use as many sheets as necessary)	Examiner Name	Howard V. Owens, Jr.
Sheet of 2	Attorney Docket Number	015200-054
MAR 0 9 2004 2		
	J.S. PATENT DOCUMENTS	
The same of the sa		

E	U.S. PATENT DOCUMENTS				
Examination Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)	

FOREIGN PATENT DOCUMENTS						
Examiner.	Document .	Kind Code	Country	Date of Publication	Translation	
Initials	Number	(if known)	Country	(MM-DD-YYYY)	Yes	No
						
			· · · · · · · · · · · · · · · · · · ·			
					ļ	
					 	

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	HENDERSON, W.R., "The Role of Leukotrienes in Inflammation", ANNALS OF INTERNAL MEDICINE 121(9):684-697 (1994) American College of Physicians
	FORD-HUTCHINSON, A.W. ET AL., "5-Lipoxygenase", ANN. REV. BIOCHEM. 63:383-417 (1994), Annual Reviews Inc.
	SAFAYHI, H. ET AL., "Boswellic Acids: Novel, Specific, Nonredox Inhibitors of 5-Lipoxygenase", J. PHARMACOL. EXP. THER. 261(3):1132-1146 (1992) The American Society for Pharmacology and Experimental Therapeutics
	ANDERSON, K.M. ET AL., "Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis", LEUKOTR. RES. 19(11):789-801, (1995) Elsevier Science Ltd.
• .	GUPTA, V.N. ET AL., "Chemistry and Pharmacology of the gum resin of B. serrata", INDIAN DRUGS 24(5):221-231
	http://ww.boswellin.com/contents.us.htm, printed 5/25/03

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO & 1449B/PTO	Complete if Known				
SECOND	Application Number	09/011,977			
INFORMATION DISCLOSURE	Filing Date	June 15, 1998			
STATEMENT BY APPLICANT	First Named Inventor	Hermann P.T. AMMON et al.			
(see as many sheets as necessary)	Examiner Name	Howard V. Owens, Jr.			
Special PET of 2	Attorney Docket Number	015200-054			

MAR	0 9 2004 E		U.S. PATENT DOCUMENTS	
Example:	Do Frient Mumber	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	5,720,975		Etzel et al.	2-24-1998
	5,888,514		Weisman	3-30-1999
			·	
·				

FOREIGN PATENT DOCUMENTS						
Examiner	Document	Kind Code	Kind Code Country	Date of Publication		lation
Initials	Number	(if known)	Country	(MM-DD-YYYY)	Yes	No
	96/19212		WIPO	06-27-1996		<u> </u>
	97/07796		WIPO	03-06-1997		
					<u> </u>	
					<u> </u>	
						<u> </u>

	NON-PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. A. KAPIL ET AL., "Anticomplementary activity of boswellic acid: an inhibitor of C3-convertase of the classical complement pathway", INT. J. IMMUNOPHARMACOL., Vol. 14, No. 7, 1992, pp. 1139-1143,
	XP000570505,
	M.L. SHARMA ET AL., "Anti-arthritic activity of boswellic acids in bovine serum albumin (BSA)- induced arthritis, INT J. IMMUNOPHARMACOL., Vol. 11, No. 6, 19989, pp. 647652, XP000572594,
	A. JANOFF, "Elastase in tissue injury", cited in the application, ANN. REV. MED., Vol. 36, 1985, pp. 207-216 XP000570622, A. Janoff,
	G.B. SINGH ET AL., "Pharmacology of an extract of salai guggal ex-Boswelia serrata, a new non-steroidal anti-inflammatory agent", AGENTS AND ACTIONS 18(3/4):407-412 (1986)
	H. SAFAYHI ET AL., "Inhibition by Boswellic Acids of Human Leukocyte Elastase", J. PHARM. EXP. THERAP 281(1):460-463 (1997).

Examiner	Date		 •		
Signature	Considered	<u></u>	 	 	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

VA 77340.1